Analyst consensus rating
Vertex Pharmaceuticals Analyst Consensus Rating
VRTX analyst consensus rating, coverage count and price target evidence.
Direct answer
Vertex Pharmaceuticals's consensus rating is Buy.
25 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $558.68.
Forecast evidence checked August 7, 2026.
Verified data
- Current price
- $484.03
- Average price target
- $558.68
- High price target
- $653.00
- Low price target
- $350.00
- Target upside
- +15.4%
- Consensus rating
- Buy
- Analysts
- 25
- Evidence date
- August 7, 2026
- Valid through
- August 14, 2026